Clinical Trial: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06961721) titled 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older' on April 23.

Brief Summary: To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine.

To evaluate the safety of the live attenuated herpes zoster vaccine.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Prevention of Herpes Zoster

Intervention: BIOLOGICAL: Herpes Zoster Vaccine, Live

assigned to the vaccine group and placebo group in a 2:1 ratio.

BIOLOGICAL: Pla...